SACRAMENTO -- California has received a shipment of 271,740 additional doses of flu vaccine and will distribute the vaccine to local health departments next week, State Public Health Officer Dr. Richard Joseph Jackson announced today.
"Because of the nationwide shortage of flu vaccine this season, these flu shots are intended for individuals who are at high risk for serious complications from the flu," Jackson said. "Those who are not in the high-risk groups should not get a flu shot."
The additional flu vaccine was purchased from Aventis-Pasteur, one of two flu vaccine manufacturers in the nation. The other manufacturer, Chiron Corp., was unable to fill orders for flu vaccine this year because of manufacturing problems. To date, the California Department of Health Services (CDHS) has provided 234,560 doses of flu vaccine to local health departments for low-income children and those enrolled in Medi-Cal or the Child Health and Disability Prevention Program.
Flu vaccine provided by CDHS, however, is not the only source of vaccine, Jackson said. Private health care providers, hospitals, long-term care facilities and some large employers have also purchased flu vaccine. Individuals seeking flu shots should contact their health care provider, clinic or local health department.
In addition, the federal Centers for Disease Control and Prevention (CDC) has announced that an additional 2.6 million doses of flu vaccine will be distributed nationwide in January.
Source: California Department of Health
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.